Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM
NCT01011049
Completed
The purpose of this study is to generate additional data on the immunogenicity and safety of revaccination with Fluzone Intradermal (ID) or Fluzone Intramuscular (IM) vaccine. Primary Objective: * To evaluate and describe the safety profile of revaccination with Fluzone ID for all participants. Secondary Objective: * To describe immunogenicity following revaccination with Fluzone ID or Fluzone IM.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/12/2016
Locations: Not set, Hoover, Alabama +44 locations
Conditions: Influenza
Register for Updates
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
NCT00613509
Terminated
Primary objective: To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment. Secondary objectives: Safety: To describe the safety profile in both treatment groups. Efficacy: To determine the objective clinical responses of patients in both treatment groups: complete response and partial response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2016
Locations: Not set, Tucson, Arizona +18 locations
Conditions: Melanoma, Cancer
Register for Updates
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
NCT00952419
Completed
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after each injection. * To describe the safety of the candidate vaccines after each injection.
Gender:
ALL
Ages:
Between 6 months and 9 years
Trial Updated:
04/12/2016
Locations: Not set, Miami Beach, Florida +19 locations
Conditions: Influenza, Swine-origin A/H1N1 Influenza
Register for Updates
A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age
NCT01258595
Completed
The aim of the study is to generate data on key parameters associated with assessment of influenza vaccines in individuals 50-64 years of age Primary Objective: * To describe the immunogenicity of High-Dose Trivalent Inactivated Influenza Vaccine (TIV) compared to TIV. * To describe the safety profile of High-Dose Trivalent Inactivated Influenza Vaccine, as assessed by solicited adverse reactions collected for 7 days post-vaccination, and unsolicited adverse events (including Serious Adverse E... Read More
Gender:
ALL
Ages:
Between 50 years and 64 years
Trial Updated:
04/12/2016
Locations: Not set, Idaho Falls, Idaho +4 locations
Conditions: Influenza
Register for Updates
Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study
NCT02500511
Completed
To determine the persistence of protective antibody levels for subjects who seroconverted after vaccination with NmVac4-A/C/Y/W-135-DT™ Participants in trial # JN-NM-002, who seroconverted for serogroups A and C will be contacted and asked to provide a blood sample at 12-24 months after vaccination with NmVac4-A/C/Y/W-135-DT. Serum Bactericidal Assays will be performed to evaluated duration of protective antibody titer for NmVac4-A/C/Y/W-135-DT for all four serogroups. To determine if subjects... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/08/2016
Locations: IRC Clinics, Towson, Maryland
Conditions: Meningococcal Meningitis, Meningococcal Infections
Register for Updates
Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer
NCT00558051
Completed
The purpose of this study is to evaluate the administration, safety and immunologic effectiveness of an experimental vaccine for colorectal cancer patients.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/31/2016
Locations: University of Cancer Institute, Pittsburgh, Pennsylvania
Conditions: Metastatic Colorectal Cancer
Register for Updates
Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone
NCT01498718
Completed
This is a Phase 1b, randomized study in healthy younger (18-50 years) and older (51-70 years) adults to evaluate the safety, tolerability, and immunogenicity of a prime-boost vaccination regimen with an investigational plasmid DNA vaccine directed towards the 2011/12 influenza vaccine strains as a prime followed 36 weeks later by the 2012/13 influenza trivalent inactivated vaccine (TIV) as the booster injection, as compared to placebo prime followed by the 2012/13 seasonal TIV. The hypothesis is... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/23/2016
Locations: Hope Clinic of the Emory Vaccine Center, Decatur, Georgia +3 locations
Conditions: Influenza
Register for Updates
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
NCT00445523
Completed
Patients with metastatic renal cell cancer will be enrolled to receive either Trovax® alone or Trovax® plus Interferon Alfa. The study will try to determine whether the use of Trovax® will delay tumor progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2016
Locations: Baylor College of Medicine - Methodist Hospital, Houston, Texas
Conditions: Carcinoma, Renal Cell
Register for Updates
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
NCT00595920
Terminated
The purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.
Gender:
ALL
Ages:
All
Trial Updated:
02/16/2016
Locations: North Central Neurology Associates, PC, Cullman, Alabama +26 locations
Conditions: Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Register for Updates
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
NCT01629589
Completed
The aim of this study is to describe immunogenicity of a single booster dose of Adacel vaccine versus Boostrix vaccine among approximately 420 adolescents 11 to \<13 years of age. Primary objective: * To describe seroprotection rates against tetanus and diphtheria in subjects randomized to receive either Adacel or Boostrix vaccine. Observational objectives: * To describe pre- and post-vaccination tetanus, diphtheria, and pertussis geometric mean antibody concentrations (GMCs) in subjects ran... Read More
Gender:
ALL
Ages:
Between 11 years and 12 years
Trial Updated:
02/02/2016
Locations: Not set, Sacramento, California +7 locations
Conditions: Tetanus, Diphtheria, Pertussis, Whooping Cough
Register for Updates
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
NCT01331161
Completed
Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular. This could be explained by a defect in the early responses of an ageing immune system. A better understanding of the basic immunological mechanisms that mediate vaccine efficacy is incomplete. Such information is critical and could greatly decrease both the cost and the time to new vac... Read More
Gender:
ALL
Ages:
Between 25 years and 79 years
Trial Updated:
01/19/2016
Locations: University of Colorado, Aurora, Colorado +1 locations
Conditions: Shingles
Register for Updates
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children
NCT00262028
Completed
The purpose of this study is to evaluate the safety and immunogenicity of Novartis (formerly Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy children ages 1 - 10 years
Gender:
ALL
Ages:
Between 12 months and 10 years
Trial Updated:
01/12/2016
Locations: Kaiser Permanente Vaccine Study Center, Oakland, California
Conditions: Prevention of Meningococcal Disease
Register for Updates